The low hepatobiliary, salivary, and lacrimal gland uptake might represent an advantage of [177Lu]Lu-labeled GRPr ligands currently under development considering the high frequency of xerostomia as an adverse effect in patients under RLT with [177Lu]Lu-PSMA-617 [27,28]. The gene discussed is FOLH1; the disease is xerostomia.